
5 Reasons You Shouldn’t Sleep on Sandler
Sales methodologies have become a hot topic in the last couple of years. As the post-COVID...
Read MoreSelect Page
Sally is a Director of Sales Enablement that is passionate about data-driven enablement. With 10+ years of experience across sales, marketing, and enablement roles, Sally contributes to the enablement community through the Revenue Enablement Society as an Associate Board Member, and can often be found helping others in the The Enablement Squad Slack.
Posted by Sally Ladrach | Jan 5, 2025 | Sales Enablement |
Sales methodologies have become a hot topic in the last couple of years. As the post-COVID...
Read MorePosted by Sally Ladrach | Nov 10, 2024 | Sales Enablement |
I recently read a book by Joshua Seiden, one he wrote to help software product teams better...
Read MorePosted by Sally Ladrach | Oct 18, 2024 | Sales Enablement |
Have you ever seen an Enablement conference keynote or webinar titled āHow Our Enablement Charter Saved the Organizationā?
Me neither.
And yet, we spend an absurd amount of time and effort finding templates, customizing them, meeting with stakeholders, explaining (for the tenth time) what exactly Revenue Enablement does, and getting all of our stakeholders to literally sign on the dotted line⦠only to end up with the same problems we had before.
We fight fires.
We become fixers of broken things.
Sellers still think of us as harbingers of pointless busywork (training), instead of strategic partners in their success.
As a profession, we in enablement give far too much stock to these charters. We cling to them like theyāre some magical shield that will save us from the chaos of stakeholder requests. We find the perfect template, make it our own, and get the “buy-in” we so desperately covet.
And yet, the same issues ariseāthe very ones we wrote a charter to save us from in the first place.
So why don’t I like charters? Here’s where I’ve seen them fail, and how we can fix it.
Read MoreThe UAE and Saudi Arabia are investing billions in US AI infrastructure. The deals could help the US in the AI race against China.
Silicon Valleyās coveted work visas are under heavy scrutiny from the Trump administration, and immigration lawyers say requests for documentation are increasing.
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 medication injected daily instead of weekly.
In response to X user queries about everything from sports to Medicaid cuts, the xAI chatbot inserted unrelated information about āwhite genocideā in South Africa.
Microsoft is limiting access to tools that boosted its rivals, but larger customers like DuckDuckGo say they wonāt be affected.